Hemato Oncology Testing Market: Advancing the Fight Against Blood Cancers
Blood cancers such as leukemia, lymphoma, and multiple myeloma demand precise, timely diagnosis to guide treatment decisions, and this need is fueling sustained expansion in the global hemato oncology testing market. The market was valued at USD 4.54 billion in 2025 and is projected to grow from USD 4.84 billion in 2026 to USD 8.45 billion by 2034, registering a CAGR of 7.2% during the forecast period, according to Fortune Business Insight. North America led the industry with a 40.96% share in 2025, according to Fortune Business Insight, underscoring the region’s strong diagnostic infrastructure and early adoption of advanced testing technologies.
Understanding Hemato Oncology Testing
Hemato oncology testing encompasses a broad range of laboratory tests used to detect, classify, and monitor blood cancers. These tests play a critical role across the patient journey — from initial screening and diagnosis to treatment selection, therapy monitoring, and relapse detection. As cancer care increasingly shifts toward precision medicine, the ability to accurately characterize a patient’s disease at the molecular level has become indispensable for clinicians aiming to deliver targeted, effective therapies.
Key Growth Drivers
Several interconnected factors are propelling market growth. The rising adoption of advanced blood cancer detection tests is a primary driver, as healthcare systems worldwide prioritize early diagnosis to improve patient outcomes. The introduction of easier-to-run, more accessible testing platforms is also expanding the reach of hemato oncology diagnostics beyond specialized centers into broader clinical settings.
The growing prevalence of blood disorders is another significant contributor. For instance, data published by the National Institutes of Health indicated an estimated 66,890 new cases of leukemia were expected to occur in the U.S. in 2025, according to Fortune Business Insight. This rising disease burden, combined with an increasing emphasis on preventive care and routine screening, continues to drive demand for diagnostic testing.
Demand for personalized cancer treatment is reshaping the competitive landscape as well. Healthcare providers are increasingly focused on delivering tailored therapies based on precise disease characterization, creating steady demand for tests capable of confirming cancer type and tracking disease signals over time. Market players are responding by expanding their tumor profiling and genomic testing portfolios. In September 2025, for example, Illumina Inc. announced strategic partnerships with pharmaceutical companies aimed at strengthening its personalized cancer care offerings, according to Fortune Business Insight.
Market Trends: The Molecular Diagnostics Shift
One of the most prominent trends shaping the industry is the rising adoption of molecular diagnostics for blood cancer screening. Molecular diagnostic tests offer higher accuracy, broader product availability, and shorter turnaround times compared to traditional methods, making them increasingly attractive to clinical laboratories. Market players are responding by launching new testing panels and assays designed to make molecular diagnostics more accessible. In March 2022, Vela Diagnostics launched a new next-generation sequencing (NGS) panel specifically designed for blood cancer screening, according to Fortune Business Insight, reflecting the broader industry shift toward molecular-based approaches.
Restraints and Challenges
Despite strong growth prospects, the market faces notable headwinds. High testing costs and inconsistent reimbursement policies remain significant restraints. Advanced hemato-oncology tests can be expensive, and coverage rules vary considerably across countries, hospitals, and insurers. Where reimbursement coverage is unclear, some hospitals limit advanced testing to select patients, constraining overall test volumes. Smaller diagnostic laboratories, meanwhile, often hesitate to add new test menus due to budgetary limitations, equipment requirements, and staffing constraints.
Maintaining consistency in test results also poses a critical challenge. Different laboratories frequently rely on varying platforms, sample handling protocols, and reporting formats, complicating result comparisons across sites. As hospitals push for faster turnaround times without compromising reliability, laboratories face mounting operational pressure to standardize methodologies, train personnel, and uphold rigorous quality control standards.
Opportunities on the Horizon
Significant opportunities exist for market participants, particularly around expanding cancer testing capabilities in hospitals and diagnostic laboratories worldwide. Facilities are prioritizing in-house testing expansion to reduce reliance on external send-out labs and accelerate clinical decision-making. Strategic partnerships between healthcare facilities and diagnostic manufacturers are expected to support this trend. A notable example came in September 2023, when Roche France, Foundation Medicine, and Gustave Roussy announced a collaboration to establish in-house liquid biopsy genomic testing capabilities at the hospital, according to Fortune Business Insight.
Segmentation Insights
By products and services, the assay kits & reagents segment commands the largest market share, driven by high test volumes and repetitive purchasing patterns, while the services segment is projected to grow at a CAGR of 7.6% through the forecast period, according to Fortune Business Insight. By cancer type, lymphoma dominated in 2025 due to its numerous subtypes requiring precise classification, while the multiple myeloma segment is expected to expand at a CAGR of 7.8%, according to Fortune Business Insight. Molecular diagnostics led the testing technology segment, and hospitals & diagnostic laboratories accounted for the largest end-user share, projected to hold 75.0% of the market in 2026, according to Fortune Business Insight.
Competitive Landscape
The market features a semi-consolidated structure dominated by established diagnostics players including F. Hoffmann-La Roche AG, Abbott, Danaher Corporation, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., and Bio-Rad Laboratories, Inc., according to Fortune Business Insight. These companies maintain their leadership through strategic collaborations aimed at advancing research capabilities. In May 2025, Danaher announced plans for a strategic collaboration to strengthen its hematology diagnostics development, according to Fortune Business Insight. Other prominent industry participants include Sysmex Corporation, Illumina, Inc., QIAGEN N.V., and BD, all of which continue prioritizing new product launches and partnerships to expand their global footprint.
Outlook
With steady technological innovation, expanding testing accessibility, and a growing global burden of blood cancers, the hemato oncology testing market is positioned for sustained growth through 2034. As molecular diagnostics continue gaining ground and personalized medicine becomes further embedded in oncology care, laboratories, hospitals, and diagnostic companies alike stand to benefit from the expanding demand for faster, more accurate, and more accessible blood cancer testing solutions.
What’s Driving Japan’s Market? Discover the Latest “Hemato Oncology Testing Market” Insights